Skip to main content

Advertisement

Fig. 3 | BMC Cancer

Fig. 3

From: Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis

Fig. 3

Comparison of Kaplan-Meier curves of progression-free survival and cancer-specific survival of metastatic renal cell carcinoma patients with treatment-free intervals <1 year and with synchronous metastases (ad) and metachronous metastases (ef) between patients receiving immunotherapy (IT) and targeted therapy (TT) according to the Heng risk groups

Back to article page